Eric Lefkofsky, Founder and CEO of Tempus, shared a post on LinkedIn:
“Even at leading academic medical centers, patients can slip through care gaps.
Despite guideline recommendations, more than 11% of patients with late-stage NSCLC, even those treated at NCI-designated cancer centers, have never been tested for an EGFR mutation.
That’s a care gap we can close. With Tempus Next, we’re working to ensure every patient receives guideline-based care.”
More posts featuring Eric Lefkofsky.